{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["42(9)"],"submitter":["Marotte H"],"funding":["Pfizer","CHU Saint-Étienne"],"pubmed_abstract":["<h4>Introduction</h4>ReFLECT was a French multicenter, observational cohort study evaluating the effectiveness and safety of CT-P13, an infliximab (IFX) biosimilar, in a real-world setting. Here, we describe the results for patients with rheumatic disease.<h4>Methods</h4>Eligible patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), or psoriatic arthritis (PsA) were recruited and received intravenous CT-P13 induction and/or maintenance therapy. Patients were either naive to IFX (IFX-naive) or had been previously treated with IFX originator or another IFX biosimilar (IFX-switched). CT-P13 persistence (primary objective) was measured as a time-dependent variable during a 2-year follow-up period. Safety was also assessed.<h4>Results</h4>The patient population comprised 142 pat"],"journal":["Advances in therapy"],"pagination":["4659-4680"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12394253"],"repository":["biostudies-literature"],"pubmed_title":["Real-World Effectiveness and Safety of Infliximab Biosimilar CT-P13 for Rheumatic Diseases: A National Observational Cohort Study (ReFLECT)."],"pmcid":["PMC12394253"],"pubmed_authors":["Kessouri M","Cantagrel A","Coury F","Brault Y","Fautrel B","Marotte H","Schaeverbeke T","Assing M"],"additional_accession":[]},"is_claimable":false,"name":"Real-World Effectiveness and Safety of Infliximab Biosimilar CT-P13 for Rheumatic Diseases: A National Observational Cohort Study (ReFLECT).","description":"<h4>Introduction</h4>ReFLECT was a French multicenter, observational cohort study evaluating the effectiveness and safety of CT-P13, an infliximab (IFX) biosimilar, in a real-world setting. Here, we describe the results for patients with rheumatic disease.<h4>Methods</h4>Eligible patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), or psoriatic arthritis (PsA) were recruited and received intravenous CT-P13 induction and/or maintenance therapy. Patients were either naive to IFX (IFX-naive) or had been previously treated with IFX originator or another IFX biosimilar (IFX-switched). CT-P13 persistence (primary objective) was measured as a time-dependent variable during a 2-year follow-up period. Safety was also assessed.<h4>Results</h4>The patient population comprised 142 pat","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-05-28T07:14:22.415Z","creation":"2026-04-08T02:24:43.691Z"},"accession":"S-EPMC12394253","cross_references":{"pubmed":["40720061"],"doi":["10.1007/s12325-025-03304-6"]}}